JPH0415770B2 - - Google Patents
Info
- Publication number
- JPH0415770B2 JPH0415770B2 JP60113080A JP11308085A JPH0415770B2 JP H0415770 B2 JPH0415770 B2 JP H0415770B2 JP 60113080 A JP60113080 A JP 60113080A JP 11308085 A JP11308085 A JP 11308085A JP H0415770 B2 JPH0415770 B2 JP H0415770B2
- Authority
- JP
- Japan
- Prior art keywords
- substance
- cells
- mast cell
- eurocidin
- substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
〔技術分野〕
本発明は、単離した肥満細胞の機能調節剤に関
するものである。
〔従来技術〕
肥満細胞は動物の結合組織内に存在し、細胞内
にケミカルメデイエーターと呼ばれる生物活性物
質を含む顆粒を数多く持つている。炎症反応及び
アレルギー反応はともに、刺激を受けた肥満細胞
が脱顆粒反応を起こし、ヒスタミン、セロトニン
などのケミカルメデイエーターを放出するところ
から始まる。免疫グロブリンEの受容体を持つ細
胞として肥満細胞が注目され、肥満細胞における
刺激の伝達機構及び脱顆粒反応の作用機作などを
解明することがアレルギー反応を理解することに
直接つながるため、肥満細胞の脱顆粒作用及び脱
顆粒抑制作用等の機能調節作用をもつ物質の開発
が望まれている。
〔目 的〕
そこで、本発明者らは、このような作用を有す
る物質が産生するか否か広く検討を行つたとこ
ろ、ストレプトベルテイシリウム属菌により生産
される既知のユーロシジン(日本農芸化学会誌
第29巻650〜652ページ、1955年)の構成成分中の
紫外線吸収スペクトルが約300〜350nmに吸収極
大(肩を含む)を示す物質が肥満細胞機能調節作
用を有することを認め、かつ市販のストレプトベ
ルテイシリウム・ユーロシジカム
(Streptoverticillium eurocidicum、IFO No.
13491)株の培養液中にも強力な肥満細胞機能調
節作用を有する物質を産生することを認め、この
物質を単離、精製した結果、上記と同一のユーロ
シジンの一成分であることを認めた。
従つて、本発明は新規な肥満細胞機能調節剤を
提供することを目的とする。
〔構 成〕
本発明は、ストレプトベルテイシリウム属菌生
産物の主成分をなすユーロシジンであつて、紫外
線吸収スペクトルが約302nm、約316nm、約
332nm及び約349nmに吸収極大を示す化合物群の
中から選ばれる少なくとも1種からなる肥満細胞
機能調節剤を提供するものである。ユーロシジン
に、肥満細胞の機能に対して機能調節作用がある
ことを見出したのは、本発明者らが初めてであ
る。
なお、本明細書中で言うユーロシジンとは、ス
トレプトベルテイシリウム属菌によつて産生され
る化合物で、下記式で表わされる基本骨格構造を
有する化合物の総称を意味するものである。
(式中、R1〜R5は水素原子又は置換基である)
本発明に係る前記特定のユーロシジン化合物
は、以下において本物質と呼称する。
本物質は、高速液体クロマトグラフイー
(HPLC)を用いて、市販のユーロシジン又はユ
ーロシジン産生微生物培養液から分離取得するこ
とができる。例えば、直径10mm、長さ250nmのカ
ラム(充填剤としてヌクレオシル5C8使用)を用
いてHPLC分離を行うと、第1図bのように分離
でき、約300〜350nmにおいて紫外線吸収スペク
トルに吸収極大を示す4種の単一化合物からなる
物質、即ち、ピークNo.1〜No.4の各ピークに相当
する物質No.1〜No.4を得ることができる。これら
の物質No.1〜No.4の紫外線吸収スペクトルを第2
図a〜dに示した。これらの物質はそれぞれ約
302nm、約316nm、約332nm、及び約349nmに吸
収極大(肩を含む)を示す。
なお、第1図は、本物質のHPLC分離結果を示
し、第1図aはユーロシジン産生微生物の培養濾
液から分離取得した本物質についての結果及び第
1図bは市販のユーロシジンについての結果を示
す。
また、本物質は、ストレプトベルテイシリウ
ム・ユーロシジカム(Streptoverticillium
eurocidicum、IFO No.13491)株又はストレプ
トベルテイシリウム・アルビレテイキユリ
(Streptoverticillium albireticuli、IFO No.
12737)株を、一般培地に培養し、培地中に産生
させ、常法により採取することができる。例え
ば、炭素源としてグルコース、シユークロース、
マルトース、デキトリン、澱粉、グリセリン等
を、窒素源としてはペプトン、肉エキス、酵母エ
キス、麦芽エキス等を用い、さらに無機塩とし
て、NaCl、K2HPO4、Na2HPO4、MgSO4等を
加えた中性液体培地中で、通気、撹拌することに
より培養される。培地のPHは5〜8、好ましくは
7付近で培養される。培養温度は通常、20〜35℃
の範囲であるが、30℃付近が好ましい。例えばグ
ルコース1.5%、ペプトン0.5%、肉エキス0.5%、
酵母エキス0.5%、NaCl0.5%を含むPH7.0の液体
培地で30℃、40時間培養することにより、本物質
を生産させることができる。
培養濾液からの採取は、有機溶媒抽出法、イオ
ン交換樹脂法、及び吸着剤を用いた吸脱着法や、
高速液体クロマトグラフイー法等を用いて行うこ
とができる。本物質は、菌体をメタノール等の有
機溶媒を用いる抽出処理した後、濃縮、結晶化等
の通常の精製操作を行うことによつても得ること
ができる。培養濾液中に含まれる物質を分離回収
するには、例えば、培養濾液中に1/10体積量のア
ンバーライトXAD−7を加えて時々撹拌しなが
ら室温で約4時間吸着処理を行つた後、アンバー
ライトXAD−7を濾別し、これを洗浄後、80%
メタノール溶液で溶出処理する。溶出液を減圧濃
縮後、水に再溶解し、PH4.0に調整した後、CM−
トヨパールイオン交換クロマトグラフイーを行う
と、0.05M酢酸−酢酸アンモニウムによるPHグラ
ジエントによりPH5.7付近から溶出が始まる。こ
の溶出液をさらにPH8.5に調整し、DEAE−トヨ
パールイオン交換クロマトグラフイーを行うとPH
7.5付近から溶出が始まる。さらに活性画分を、
MCIゲルCHP−20P吸着カラムに吸着させ、40%
アセトニトリル溶出画分を分取し、減圧乾固する
ことにより本物質のうち物質No.3を得ることがで
きる。
次に、本物質の肥満細胞脱顆粒抑制活性の試験
方法及びその結果を以下に示す。
ラツト腹腔内より腹水を採取し、4℃、150×
gの条件で10分間遠心した後、沈澱した細胞を、
牛血清アルブミン重層遠心法等での方法により分
離し、肥満細胞画分を得た。これを0.2%牛血清
アルブミンを含むタイロード液に肥満細胞が106
個/mlとなるように懸濁し、肥満細胞浮遊液を得
た。次に被験化合物を生理食塩水20μlに肥満細胞
浮遊液20μlを入れて混和し、37℃で10分間反応さ
せた後、脱顆粒誘発剤として5μg/mlのコンパウ
ンド(compound)48/80溶液10μl(最終濃度で
1μg/ml)を加えて10分間反応させ、氷冷後遠心
して上澄を採つた。上澄に含まれるヒスタミンを
HPLC法(Onda等、Hiroshima、J.Med.Sci.,
第27巻、93〜97ページ、1978年)により定量する
ことにより脱顆粒状態を測定した。
なお、前記脱顆粒誘発剤としては、コンパウン
ド48/80(シグマ社製)の他に、コンカナバリン
A(和光純薬工業(株)社製)、イオノフオアA23187
(カルビオケム・ベーリング社製)はじめ、抗原
抗体反応を利用したものなど一般に知られている
任意の薬剤もしくは方法を用いることができる。
次に、被験化合物の濃度を種々変えて測定を行
い、本測定系で1μg/mlのコンパウンド48/80に
より誘発される肥満細胞脱顆粒を50%抑制する化
合物の濃度〔IC50〕値を求めた。また、コンパウ
ンド48/80の存在しない状態や、コレステロール
を添加した状態など各種の条件下で本物質の肥満
細胞に対する機能調節作用の測定も合せて行い、
その結果は以下に示すように、本物質には、強い
肥満細胞機能調節作用をもつことが認められた。
(1) 本物質はいずれも、低濃度領域では肥満細胞
脱顆抑制作用を示し、そのIC50値は下記の表−
1に示す通りであつた。
(2) 本物質は、上記(1)の作用を示す濃度より高濃
度領域では、単独で肥満細胞脱顆粒作用を示
し、本作用は反応液のカルシウムイオン濃度に
依存していた。
(3) 上記(1)及び(2)の作用は、ステロール骨格を有
する物質の添加によりその作用の強さを減じる
ことも可能であつた。
なお、本測定系で1μg/mlのコンパウンド48/8
0により誘発される肥満細胞脱顆粒作用を50%抑
制する化合物の濃度を1単位/ml〔1ユニツト/
ml〕とした。
[Technical Field] The present invention relates to an agent for regulating the function of isolated mast cells. [Prior Art] Mast cells exist in the connective tissue of animals, and have many granules containing biologically active substances called chemical mediators inside the cells. Both inflammatory and allergic reactions begin when stimulated mast cells undergo a degranulation reaction and release chemical mediators such as histamine and serotonin. Mast cells have attracted attention as cells that have receptors for immunoglobulin E, and elucidating the stimulation transmission mechanism and degranulation reaction mechanism in mast cells will directly lead to understanding allergic reactions. It is desired to develop a substance that has functional regulating effects such as degranulation and degranulation inhibiting effects. [Purpose] Therefore, the present inventors extensively investigated whether a substance with such an effect could be produced, and found that the known eurocidin produced by Streptoverteicillium (Japanese Society of Agricultural Chemistry Journal)
Vol. 29, pp. 650-652, 1955), it was recognized that substances whose ultraviolet absorption spectra exhibit maximum absorption in the wavelength range of about 300 to 350 nm (including the shoulder) have a mast cell function regulating effect, and commercially available Streptoverticillium eurocidicum (IFO No.
13491) was found to produce a substance that has a strong mast cell function regulating effect in the culture solution, and as a result of isolation and purification of this substance, it was confirmed that it is a component of the same eurocidin as above. . Therefore, an object of the present invention is to provide a novel mast cell function regulator. [Configuration] The present invention relates to eurocidin, which is the main component of the product of Streptoverteicillium bacteria, and whose ultraviolet absorption spectrum is approximately 302 nm, approximately 316 nm, and approximately 302 nm, approximately 316 nm, and approximately
The present invention provides a mast cell function regulator comprising at least one compound selected from a group of compounds exhibiting maximum absorption at 332 nm and about 349 nm. The present inventors are the first to discover that eurocidin has a functional regulatory effect on mast cell function. The eurocidin referred to herein is a compound produced by Streptoverteicillium bacteria, and is a general term for compounds having a basic skeleton structure represented by the following formula. (In the formula, R 1 to R 5 are hydrogen atoms or substituents.) The specific eurocidin compound according to the present invention is hereinafter referred to as the present substance. This substance can be isolated and obtained from commercially available eurocidin or a culture solution of eurocidin-producing microorganisms using high performance liquid chromatography (HPLC). For example, when HPLC separation is performed using a column with a diameter of 10 mm and a length of 250 nm (using Nucleosil 5C8 as a packing material), the separation shown in Figure 1b is obtained, and the ultraviolet absorption spectrum exhibits an absorption maximum at approximately 300 to 350 nm. Substances consisting of four types of single compounds, that is, substances No. 1 to No. 4 corresponding to each of peaks No. 1 to No. 4 can be obtained. The ultraviolet absorption spectra of these substances No. 1 to No. 4 were
Shown in Figures a-d. Each of these substances is approximately
It exhibits absorption maxima (including a shoulder) at 302 nm, about 316 nm, about 332 nm, and about 349 nm. Furthermore, Figure 1 shows the HPLC separation results of this substance, Figure 1a shows the results for this substance separated and obtained from the culture filtrate of a eurocidin-producing microorganism, and Figure 1b shows the results for commercially available eurocidin. . In addition, this substance is Streptoverticillium eurocidicum (Streptoverticillium
eurocidicum, IFO No. 13491) strain or Streptoverticillium albireticuli, IFO No.
12737) strain can be cultured in a general medium, produced in the medium, and collected by a conventional method. For example, glucose, sucrose,
Maltose, dextrin, starch, glycerin, etc. are used as nitrogen sources, peptone, meat extract, yeast extract, malt extract, etc. are used as nitrogen sources, and inorganic salts such as NaCl, K 2 HPO 4 , Na 2 HPO 4 , MgSO 4 are added. The cells are cultured in a neutral liquid medium with aeration and agitation. The culture medium is cultured at a pH of 5 to 8, preferably around 7. Culture temperature is usually 20-35℃
The temperature is preferably around 30°C. For example, glucose 1.5%, peptone 0.5%, meat extract 0.5%,
This substance can be produced by culturing at 30°C for 40 hours in a pH 7.0 liquid medium containing 0.5% yeast extract and 0.5% NaCl. Collection from culture filtrate can be performed using organic solvent extraction method, ion exchange resin method, adsorption/desorption method using adsorbent,
This can be carried out using high performance liquid chromatography or the like. This substance can also be obtained by extracting bacterial cells using an organic solvent such as methanol, followed by conventional purification operations such as concentration and crystallization. To separate and recover the substances contained in the culture filtrate, for example, add 1/10 volume of Amberlite XAD-7 to the culture filtrate and perform adsorption treatment at room temperature for about 4 hours with occasional stirring. After filtering Amberlite XAD-7 and washing it, 80%
Elute with methanol solution. After concentrating the eluate under reduced pressure, redissolving it in water and adjusting the pH to 4.0, CM-
When Toyopearl ion exchange chromatography is performed, elution begins at around pH 5.7 using a pH gradient of 0.05M acetic acid-ammonium acetate. This eluate was further adjusted to pH 8.5 and subjected to DEAE-Toyopearl ion exchange chromatography.
Elution begins around 7.5. Furthermore, the active fraction
Adsorbed on MCI gel CHP-20P adsorption column, 40%
Substance No. 3 of this substance can be obtained by separating the acetonitrile elution fraction and drying it under reduced pressure. Next, the test method and results for the mast cell degranulation inhibitory activity of this substance are shown below. Ascitic fluid was collected from the rat's peritoneal cavity, 4℃, 150×
After centrifuging for 10 minutes under the conditions of g, the precipitated cells were
Bovine serum albumin was separated by a method such as multilayer centrifugation to obtain a mast cell fraction. 106 mast cells were added to Tyrode's solution containing 0.2% bovine serum albumin.
A mast cell suspension was obtained by suspending the mast cells at cells/ml. Next, the test compound was mixed with 20 μl of the mast cell suspension in 20 μl of physiological saline, and the mixture was allowed to react at 37°C for 10 minutes. at final concentration
1 μg/ml) was added and reacted for 10 minutes, cooled on ice, centrifuged, and the supernatant was collected. The histamine contained in the supernatant
HPLC method (Onda et al., Hiroshima, J.Med.Sci.,
27, pp. 93-97, 1978). In addition, as the degranulation inducing agent, in addition to Compound 48/80 (manufactured by Sigma), Concanavalin A (manufactured by Wako Pure Chemical Industries, Ltd.), Ionophore A23187
(manufactured by Calbiochem Behring) and any commonly known drugs or methods such as those utilizing antigen-antibody reactions can be used.
Next, measurements were performed with various concentrations of the test compound, and the concentration [IC 50 ] value of the compound that inhibited 50% of mast cell degranulation induced by 1 μg/ml Compound 48/80 using this measurement system was determined. Ta. In addition, we also measured the functional regulatory effect of this substance on mast cells under various conditions, including in the absence of Compound 48/80 and in the presence of cholesterol.
As shown in the results below, this substance was found to have a strong mast cell function regulating effect. (1) All of these substances exhibit an inhibitory effect on mast cell decondylation at low concentrations, and their IC 50 values are shown in the table below.
It was as shown in 1. (2) This substance independently exhibited a mast cell degranulation effect in a concentration range higher than the concentration exhibiting the effect described in (1) above, and this effect was dependent on the calcium ion concentration of the reaction solution. (3) It was also possible to reduce the strength of the effects (1) and (2) above by adding a substance having a sterol skeleton. In addition, in this measurement system, compound 48/8 with a concentration of 1μg/ml
The concentration of the compound that inhibits 50% of the mast cell degranulation effect induced by 1 unit/ml [1 unit/ml]
ml].
次に、本発明を実施例によりさらに詳細に説明
する。
実施例 1
グルコース1.5%、ペプトン0.5%、肉エキス0.5
%、酵母エキス0.5%、NaCl0.5%を含むPH7.0の
液体培地100mlを500mlの坂口フラスコに分注し、
120℃、20分間滅菌する。この培地に放線菌スト
レプトベルテイシリウム・ユーロシジカム株の斜
面寒天培地より1白金耳量を接種し、30℃、3日
間往復しんとう培養を行つた。この培養液と同組
成の培地20を30用ジヤーフアーメンターに仕
込み、ストレプトベルテイシリウム・ユーロシジ
カム株の前培養液300mlをこの培地に移し、30℃、
200回転、通気量毎分10で40時間培養を行つた。
培養終了後、7000回転の連続遠心を行うことによ
り、菌体と培養濾液を分離し、黒かつ色の培養濾
液18を得た。この培養濾液の肥満細胞脱顆粒抑
制活性は642500ユニツトであつた。
実施例 2
実施例1で得た菌体に5倍量のメタノールを加
えて撹拌後、室温にて放置した。時々撹拌しなが
ら24時間置いた後、菌体を濾別後、メタノール抽
出液を濃縮し、乾固した。得られた残渣をメタノ
ールを用いて再溶解させ、可溶性画分のみを採つ
た。再度濃縮後、生成する結晶性のユーロシジン
含有物質を得た。本物質の肥満細胞に対する活性
は約113000ユニツトであつた。
実施例 3
市販のユーロシジン(武田薬品工業(株)製)をメ
タノールに溶解させ、HPLCにて分離した。この
場合の分離条件は次の通りである。
カラム:ヌクレオシル5C8充填、直径10mn、
長さ250mm
使用溶剤:アセトニトリル/酢酸アンモニウム
緩衝液(0.01M、PH5.0)=35/65
流 速:4ml/分
検 出:紫外波長350nmにおける吸光度測定
試料濃度:0.2mg/ml
注入量:200μl
上記条件により市販のユーロシジンの構成成分
を分離したところ、第1図bのような各成分の分
離結果を示し、該当するピークに相当する物質No.
1〜No.4の画分を得た。各画分を減圧濃縮後、凍
結乾燥をくり返し、物質No.1〜No.4を得た。この
物質No.1〜No.4の紫外線吸収スペクトルは第2図
a〜dに示す通り、各物質はそれぞれ約302nm、
約316nm、約332nm及び約349nmに吸収極大(肩
を含む)を示した。
実施例 4
(1) 実施例1で得られた培養濾液のうち5中
に、1/10本体積に相当する吸着剤アンバーライ
トXAD−7を加え、時々振とうしながら4時
間室温にて吸着処理した。吸引濾過により、吸
着剤を濾別し、精製水で洗浄した後、吸着剤体
積の2倍量に相当する20%メタノール水溶液で
洗浄した。その後、吸着剤体積の3倍量に相当
する80%メタノール水溶液で溶出させ、溶出液
を減圧濃縮した後、精製水に溶解させた。ほぼ
100%近い活性が回収できた。
(2) 次に、CM−トヨパール650Mカラム〔東洋
曹達工業製、カラム体積533ml、0.05M酢酸−
酢酸アンモニウム(PH4.0)で平衡化〕にPH4.0
に調整した試料溶液を吸着させ、0.05M酢酸−
酢酸アンモニウム(PH6.0)で溶出させた。最
も強い活性画分は溶出液のPH5.7から溶出して
きた。活性画分の肥満細胞脱顆粒抑制活性は
25250ユニツトであつた。
(3) さらに上記(2)の活性画分を、PH8.5に調整し
た後、DEAE−トヨパール650Mカラム〔東洋
曹達工業製、カラム体積179ml、0.05M酢酸ア
ンモニウム−アンモニア水でPH8.5に平衡化〕
に、吸着させ、0.05M酢酸アンモニウム−アン
モニア水(PH7.5)で溶出させた。この活性画
分の活性は、16500ユニツトであつた。
(4) さらに、MCIゲル(CHP−20P、三菱化成
製)を充填した吸着カラム(カラム体積40ml)
に、前記(3)で得られた活性画分を吸着させ、20
%アセトニトリル水溶液で洗浄後、40%アセト
ニトリル水溶液で溶出させ、減圧濃縮して白色
物質を得た。本物質をメタノールに溶解して、
紫外線吸収スペクトルを測定し、さらに前記実
施例3で示した分離条件によりHPLC分離を行
い。その結果を各々第1図a及び第3図に示し
た。得られた物質は市販のユーロシジンの構成
成分のうち物質No.3と同じものであつた。活性
量は12500ユニツトであつた。
実施例 5
(1) ウイスター系雌性ラツト(体重150〜250g)
を脱血致死させ、腹腔内にタイロード液を20ml
注入し、腹部を約2分間軽くマツサージした。
開腹後腹水を採取し、4℃にて150×g、10分
間の条件で遠心分離し、沈澱する細胞を集め
た。この細胞をタイロード液2mlに懸濁させ、、
比重1.068に調整した牛血清アルブミン含有生
理食塩水4mlに重層し、4℃、100×gの条件
で12分間遠心分離後、沈澱する細胞を集めた。
タイロード液で2回洗浄した後、0.2%牛血清
アルブミンを含むタイロード液に肥満細胞が約
106個/mlとなるように懸濁させ、肥満細胞浮
遊液を得た。
(2) 被験化合物を含む生理食塩水20μlと肥満細胞
浮遊液20μlを10分間37℃にて反応させ、最終濃
度1μg/mlとなるようにコンパウンド48/80溶
液10μlを加え、さらに10分間反応させた。反応
後1分間氷冷した後、1500×g、4分間の条件
で遠心し、上澄と細胞とを分離した。上澄は前
記OndaらのHPLC法に従つてヒスタミンの蛍
光定量を行い、その値を0.05%トライトンX−
100で完全に細胞を壊した時のヒスタミン量を
100とした相対値で表わした。
(3) 1μg/mlのコンパウンド48/80の誘発する肥
満細胞脱顆粒作用に対して物質No.1〜No.4の示
した作用は次の通りであつた。
(3) (i)
物質No.1〜No.4はいずれも低濃度領域では肥満
細胞脱顆粒抑制作用を示し、物質No.1及びNo.3の
IC50値はともに4μg/mlであつた。物質No.2及び
No.4は微量成分であり、定量的に測定することは
困難であつたが、物質No.1及びNo.3と同様の活性
を有していた。
(3) (ii)
物質No.1〜No.4は高濃度領域では単独で肥満細
胞脱顆粒作用を示し、本作用は、反応液のカルシ
ウムイオン濃度を約1mM以上にした時に発現し、
反応液のカルシウムイオン濃度が0に近い時は発
現しないというカルシウムイオン依存性を示し
た。
(3) (iii)
反応液にコレステロールを一定濃度(約2μg/
ml)以上加えることにより、上記(3)−(i)及び(3)−
(ii)の作用はコレステロールに対して濃度依存的に
減少した。
Next, the present invention will be explained in more detail with reference to Examples. Example 1 Glucose 1.5%, peptone 0.5%, meat extract 0.5
%, yeast extract 0.5%, and PH7.0 liquid medium containing 0.5% NaCl was dispensed into a 500 ml Sakaguchi flask.
Sterilize at 120℃ for 20 minutes. One platinum loop of the actinomycete Streptoverteicillium eurocidicum strain was inoculated onto this medium from a slanted agar medium, and cultured with reciprocating shakes at 30°C for 3 days. A medium 20 with the same composition as this culture solution was placed in a jar fermenter for 30, and 300 ml of the preculture solution of Streptoverteicillium eurocidicum strain was transferred to this medium, and the mixture was heated at 30°C.
Culture was carried out for 40 hours at 200 rotations and an air flow rate of 10 per minute.
After the culture was completed, the bacterial cells and the culture filtrate were separated by continuous centrifugation at 7000 rpm to obtain a black culture filtrate 18. The mast cell degranulation inhibitory activity of this culture filtrate was 642,500 units. Example 2 Five times the amount of methanol was added to the bacterial cells obtained in Example 1, stirred, and then left at room temperature. After leaving for 24 hours with occasional stirring, the bacterial cells were filtered off, and the methanol extract was concentrated and dried. The obtained residue was redissolved using methanol, and only the soluble fraction was collected. After re-concentration, the resulting crystalline eurocidin-containing material was obtained. The activity of this substance against mast cells was approximately 113,000 units. Example 3 Commercially available Eurocidin (manufactured by Takeda Pharmaceutical Co., Ltd.) was dissolved in methanol and separated by HPLC. The separation conditions in this case are as follows. Column: Nucleosil 5C8 packed, diameter 10mn,
Length 250mm Solvent used: Acetonitrile/ammonium acetate buffer (0.01M, PH5.0) = 35/65 Flow rate: 4ml/min Detection: Absorbance measurement at ultraviolet wavelength 350nm Sample concentration: 0.2mg/ml Injection volume: 200μl When the constituent components of commercially available Eurocidin were separated under the above conditions, the separation results of each component were shown in Figure 1b, and the substance No. corresponding to the corresponding peak was shown.
Fractions No. 1 to No. 4 were obtained. After concentrating each fraction under reduced pressure, freeze-drying was repeated to obtain substances No. 1 to No. 4. The ultraviolet absorption spectra of these substances No. 1 to No. 4 are shown in Figure 2 a to d, each substance has a wavelength of about 302 nm,
It showed absorption maxima (including a shoulder) at about 316 nm, about 332 nm, and about 349 nm. Example 4 (1) Add the adsorbent Amberlite XAD-7 equivalent to 1/10 volume to 5 of the culture filtrate obtained in Example 1, and adsorb at room temperature for 4 hours with occasional shaking. Processed. The adsorbent was separated by suction filtration, washed with purified water, and then washed with a 20% aqueous methanol solution equivalent to twice the volume of the adsorbent. Thereafter, it was eluted with an 80% aqueous methanol solution equivalent to three times the volume of the adsorbent, and the eluate was concentrated under reduced pressure and then dissolved in purified water. almost
Nearly 100% activity was recovered. (2) Next, CM-Toyopearl 650M column [manufactured by Toyo Soda Kogyo Co., Ltd., column volume 533ml, 0.05M acetic acid]
Equilibrate with ammonium acetate (PH4.0)] to PH4.0
Adsorb the sample solution adjusted to 0.05M acetic acid.
Elution was performed with ammonium acetate (PH6.0). The most strongly active fraction was eluted from the eluate at pH 5.7. The mast cell degranulation inhibitory activity of the active fraction is
It was 25,250 units. (3) Furthermore, after adjusting the active fraction from (2) above to pH 8.5, DEAE-Toyopearl 650M column [manufactured by Toyo Soda Kogyo Co., Ltd., column volume 179 ml, equilibrated to pH 8.5 with 0.05 M ammonium acetate-ammonia water. ]
It was adsorbed on the solution and eluted with 0.05M ammonium acetate-ammonia water (PH7.5). The activity of this active fraction was 16,500 units. (4) Furthermore, an adsorption column (column volume 40ml) packed with MCI gel (CHP-20P, manufactured by Mitsubishi Kasei)
The active fraction obtained in (3) above was adsorbed onto the
After washing with a 40% acetonitrile aqueous solution, the mixture was eluted with a 40% acetonitrile aqueous solution and concentrated under reduced pressure to obtain a white substance. Dissolve this substance in methanol,
Ultraviolet absorption spectra were measured, and HPLC separation was performed under the separation conditions shown in Example 3 above. The results are shown in FIG. 1a and FIG. 3, respectively. The obtained substance was the same as substance No. 3 among the constituent components of commercially available Eurocidin. The amount of activity was 12,500 units. Example 5 (1) Female Wistar rat (weight 150-250g)
Bleed to death and inject 20 ml of Tyrode's solution intraperitoneally.
The abdomen was lightly massaged for about 2 minutes.
Ascites fluid was collected after laparotomy and centrifuged at 150 xg for 10 minutes at 4°C to collect precipitated cells. The cells were suspended in 2 ml of Tyrode's solution,
The cells were layered on 4 ml of physiological saline containing bovine serum albumin adjusted to a specific gravity of 1.068, and centrifuged at 4° C. and 100×g for 12 minutes, and the precipitated cells were collected.
After washing twice with Tyrode's solution, the mast cells were placed in Tyrode's solution containing 0.2% bovine serum albumin.
The mast cells were suspended at a concentration of 10 6 cells/ml to obtain a mast cell suspension. (2) 20 μl of physiological saline containing the test compound and 20 μl of the mast cell suspension were reacted for 10 minutes at 37°C, then 10 μl of compound 48/80 solution was added to give a final concentration of 1 μg/ml, and the mixture was allowed to react for an additional 10 minutes. Ta. After the reaction, the mixture was cooled on ice for 1 minute and then centrifuged at 1500 xg for 4 minutes to separate the supernatant and cells. The supernatant was subjected to fluorescence quantification of histamine according to the HPLC method of Onda et al., and the value was determined using 0.05% Triton
The amount of histamine when cells are completely destroyed at 100
Expressed as a relative value set to 100. (3) The effects of substances No. 1 to No. 4 on the mast cell degranulation effect induced by Compound 48/80 at 1 μg/ml were as follows. (3) (i) Substances No. 1 to No. 4 all exhibit an inhibitory effect on mast cell degranulation at low concentrations;
Both IC 50 values were 4 μg/ml. Substance No. 2 and
Although No. 4 was a trace component and difficult to quantitatively measure, it had the same activity as Substances No. 1 and No. 3. (3) (ii) Substances No. 1 to No. 4 independently exhibit a mast cell degranulation effect in the high concentration range, and this effect is expressed when the calcium ion concentration of the reaction solution is increased to approximately 1 mM or higher.
It showed calcium ion dependence, which was not expressed when the calcium ion concentration of the reaction solution was close to 0. (3) (iii) Add cholesterol to the reaction solution at a constant concentration (approximately 2 μg/
ml) or more, the above (3)-(i) and (3)-
The effect of (ii) on cholesterol decreased in a concentration-dependent manner.
第1図は、高速液体クロマトグラフイーによる
分離結果を示すグラフで、第1図aは培養濾液中
から精製された肥満細胞機能調節物質についての
結果、第1図bは市販のユーロシジンについての
結果を示す。第1図において、縦軸は350nmの紫
外線吸収の強度、横軸は溶出時間(分)を示し、
第1図b中のNo.1〜No.4は各ピークに相当する市
販のユーロシジンの構成成分を示す。第2図は市
販のユーロシジンの構成成分中の物質No.1〜No.4
の紫外線吸収スペクトルを示し、縦軸は紫外吸収
の強度、横軸は波長(nm)を示す。第2図の図
a〜dは、それぞれ第1図bの各ピークに相当す
る物質No.1〜No.4の紫外線吸収スペクトルを示
す。第3図は紫外線吸収スペクトル図を示し、曲
線bは市販のユーロシジンの構成成分中物質(No.
3相当物質)及び曲線aは培養濾液中から精製さ
れた肥満細胞機能調節物質(No.3相当物質)の紫
外線吸収スペクトルを示す。縦軸は、紫外吸収の
強度、横軸は波長(nm)を示す。
Figure 1 is a graph showing the separation results by high-performance liquid chromatography; Figure 1a is the result for a mast cell function regulator purified from the culture filtrate, and Figure 1b is the result for commercially available Eurocidin. shows. In Figure 1, the vertical axis shows the intensity of ultraviolet absorption at 350 nm, and the horizontal axis shows the elution time (minutes).
No. 1 to No. 4 in FIG. 1b indicate the constituent components of commercially available Eurocidin corresponding to each peak. Figure 2 shows substances No. 1 to No. 4 in the constituent components of commercially available Eurocidin.
The figure shows the ultraviolet absorption spectrum of , where the vertical axis shows the intensity of ultraviolet absorption and the horizontal axis shows the wavelength (nm). Figures a to d in Figure 2 show the ultraviolet absorption spectra of substances No. 1 to No. 4 corresponding to the respective peaks in Figure 1 b, respectively. Figure 3 shows an ultraviolet absorption spectrum diagram, and curve b shows a substance in the constituent components of commercially available Eurocidin (No.
Curve a shows the ultraviolet absorption spectrum of the mast cell function regulating substance (substance equivalent to No. 3) purified from the culture filtrate. The vertical axis shows the intensity of ultraviolet absorption, and the horizontal axis shows the wavelength (nm).
Claims (1)
成分をなすユーロシジンであつて、紫外線吸収ス
ペクトルが約302nm、約316nm、約332nm及び約
349nmに吸収極大を示す化合物群の中から選ばれ
る少なくとも1種からなる肥満細胞機能調節剤。1. Eurocidin, which is the main component of Streptoverteicillium products, has an ultraviolet absorption spectrum of about 302 nm, about 316 nm, about 332 nm, and about
A mast cell function regulator comprising at least one compound selected from a group of compounds that exhibit maximum absorption at 349 nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60113080A JPS6216425A (en) | 1985-05-28 | 1985-05-28 | Mast cell function regulator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60113080A JPS6216425A (en) | 1985-05-28 | 1985-05-28 | Mast cell function regulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6216425A JPS6216425A (en) | 1987-01-24 |
| JPH0415770B2 true JPH0415770B2 (en) | 1992-03-19 |
Family
ID=14602971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60113080A Granted JPS6216425A (en) | 1985-05-28 | 1985-05-28 | Mast cell function regulator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6216425A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04129236U (en) * | 1991-05-20 | 1992-11-25 | 積水化学工業株式会社 | eaves gutter equipment |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61227528A (en) * | 1985-04-02 | 1986-10-09 | Agency Of Ind Science & Technol | Mast cell function regulator |
-
1985
- 1985-05-28 JP JP60113080A patent/JPS6216425A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6216425A (en) | 1987-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2917305B2 (en) | FR-901155 substance and production method thereof | |
| JP3083369B2 (en) | Teicoplanin recovery method | |
| JPH0415770B2 (en) | ||
| EP0710290B1 (en) | Method for precipitating natural avermectins, and fermentative production of the same | |
| JPH07113024B2 (en) | Method for purifying pyrroloquinoline quinone | |
| US4347184A (en) | Process for separating and recovering coproporphyrin and uroporphyrin from a culture broth containing them | |
| US2967177A (en) | Process of antibiotic purification | |
| EP0138708B1 (en) | Isoefrotomycin | |
| US3089816A (en) | Lemacidine and process for its manufacture | |
| JP3067183B2 (en) | Method for producing FR900506 substance | |
| JPH064669B2 (en) | Polyene substance and obesity function regulator | |
| JPS61227528A (en) | Mast cell function regulator | |
| JPH0429356B2 (en) | ||
| JPS6225156B2 (en) | ||
| JP2690779B2 (en) | L-ascorbic acid derivative and method for producing the same | |
| JPH101496A (en) | Avermectin purification method | |
| JPH0367077B2 (en) | ||
| KR840001657B1 (en) | Process for the preparation of mycoplanecin derivatives | |
| JPS6321480B2 (en) | ||
| JPH0123473B2 (en) | ||
| JPH06503327A (en) | 13-demethyl FR-900506 derivative and its use as an immunosuppressant | |
| JP2005295897A (en) | Method for producing antibiotic YL-02729S substance | |
| JPH0283394A (en) | Purification method of S-adenosyl-L-homocysteine | |
| JPH03216194A (en) | Preparation of saccharide amino acid ester | |
| JPH0673083A (en) | Novel glycolytic enzyme inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term | ||
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |